DNMT3B and germinoma: Although it remains to be experimentally tested, our observation that DNMT3B is expressed at significantly higher levels in YSTs than in germinomas provides a possible explanation for this difference and, as YSTs exhibit a more aggressive natural history than germinomas, a target for potential therapy.